You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Seretide in paediatric patients
(4 to 12 years)

Summary of the BADGER study in paediatric asthma[1]

The BADGER (Best ADd-on therapy Giving Effective Responses) study provides a clinical assessment of Step-up treatments for children 6-17 years of age with asthma, who were uncontrolled on a low dose inhaled corticosteroid.[1]

The BADGER study provided robust evidence that patients were significantly more likely to have the best response when given long-acting beta2-agonist (LABA) step-up therapy rather than increasing the dose of ICS, (relative probability of 70%, p=0.004) or adding in a LTRA, (relative probability 60%, p=0.002).[1]


Both the Seretide Diskus 50/100 mcg and the Seretide Evohaler 25/50 mcg (with or without spacer) are indicated in the regular treatment of asthma for paediatric patients not adequately controlled with:

  • inhaled corticosteroids. [3]
  • 'as needed' inhaled short- acting β2 agonist [2],[3]

The BTS/SIGN Guidelines advocate that the aim of asthma treatment should be achieving symptom control early and maintaining that control. At step 3, addition of a LABA is proposed as the first choice add-on therapy and use of combination ICS/LABA is also recommended in paediatric patients between 5 and 12 years and adults (12+yrs).[4]

Seretide, Diskus and Evohaler are registered trademarks of the GlaxoSmithKline Group of Companies